Licensing Agreement with Peptris Technologies

Revio has in-licensed rights to the early preclinical-stage asset and related IP for all types of muscular dystrophy. Under the agreement, Revio holds global rights, while Peptris retains rights across BRICS markets. Revio is progressing the asset through ongoing efficacy studies and will seek regulatory agency feedback via a pre-IND meeting in the second half of the year towards initiating a Phase 2 clinical program. Financial terms were not disclosed.

Poster Presentation at the 2025 MDA Conference

Revio and Peptris will be presenting the preclinical efficacy data as a late-breaking poster at the Muscular Dystrophy Association Conference, Mar 16-19, 2025, in Dallas, Texas.

Promising Preclinical Efficacy Data & Next Steps

Preclinical data demonstrate RT001’s efficacy in improving muscle strength, functional measures and biomarkers, both as a single agent and in combination with deflazacort, a standard-of-care corticosteroid in DMD.

Revio stated, “We are excited to partner Peptris on this promising small-molecule drug, which may function independent of dystrophin gene mutations. Given its strong safety record from the previous approved indication and the current preclinical efficacy in DMD, RT001 is well-positioned as a Phase 2-ready asset for development via the 505(b)(2)/hybrid pathway. We will discuss our development plans with regulators later this year at a pre-IND meeting and apply for an orphan designation. There is significant unmet need for safe, effective, mutation-agnostic therapies in DMD and if these results translate clinically, RT001 could address this need efficiently”.

According to Peptris, “The agreement represents an important step in our mission to leverage AI-driven drug discovery for high-impact therapeutic advancements. Peptris has a pipeline of advanced preclinical assets in Rare Diseases, Alopecia, Inflammation and Oncology. We are confident that Revio Therapeutics’ expertise in repurposing medicines will accelerate the clinical development of PEPR124 (RT001) to benefit DMD patients”.

About Revio Therapeutics LLP

Revio Therapeutics is a privately held specialty pharmaceutical start-up focused on repurposing and optimizing approved medicines by expanding their use into new indications or improving their efficacy and safety towards better outcomes. Revio is building a deep portfolio of novel programs spanning therapeutic areas and is led by an experienced team with a proven track record of drug development successes. Revio is backed by a Hyderabad-based family office with a pioneering presence in the Indian venture capital space and a successful track record of enterprise building across verticals.

For more information about Revio, visit www.reviotx.com or contact info@reviotx.com.

About Peptris Technologies Pvt Ltd

Peptris Technologies is an AI powered preclinical drug discovery company with a healthy pipeline of preclinical assets in development. Peptris leverages proprietary AI algorithms to discover novel molecules and repurpose drugs, significantly reducing the time and cost of drug discovery. Peptris Technologies, based out of CCAMP, Bangalore, India.  was funded by Speciale Investments and is currently in the process of raising another round of funding to accelerate its drug discovery efforts.

For more information, please visit www.peptris.com or contactinfo@peptris.com.